



Spectrophotometric Investigations for Simultaneous Analysis of Certain Antibacterial: A Brief Review

Farah Nouri Jasim¹  and Nahla A. Alassaf^{2*} 

^{1,2}Department of Chemistry, College of Education for Pure Science (Ibn Al-Haitham), University of Baghdad, Baghdad, Iraq.

*Corresponding Author.

Received: 5 April 2023

Accepted: 25 July 2023

Published: 20 April 2025

doi.org/10.30526/38.2.3385

Abstract

Antibacterial substances belong to a group of compounds that attack dangerous microorganisms. Therefore, killing bacteria or reducing their metabolic activity will lessen their adverse effects on a biological system. They originated from either synthetic materials, microbes, or mold. Many of these medications treat the gram-negative bacteria from the critical precedence group, such as pseudomonas, carbapenem-resistant acinetobacter, and enterobacterales. This study aims to investigate the simultaneous analysis of specific antibacterial spectrophotometrically. The WHO maintains this list of priority infections with antibiotic resistance. Drug combinations in single dosage forms are becoming increasingly popular in the pharmaceutical industry. This has created a significant issue for pharmaceutical administrators, particularly in combating fake medications and pharmaceutical analysts and developing reliable and accurate methodologies with minimal overlapping effects on quantification. The basics of several spectrophotometric methods utilized to conduct multi-component analysis are collected in the current work, and the validation criteria that are an essential component of the approaches are also described. Numerous analytical techniques, including high-performance liquid chromatography, electrochemical methods, flow injection techniques, gas chromatography, spectrofluorometric techniques, capillary electrophoresis, and spectrophotometric techniques, have been reported to determine antibacterials. This study conducts a concise narrative evaluation of the many spectrophotometric methods that have been published for the simultaneous investigation of Levofloxacin, Sulfamethoxazole, Metronidazole, and Rifampicin in their pure forms, pharmaceutical dosage forms, and biological samples due to their sensitivity, simplicity, and cost-effectiveness.

Keywords: Antibacterial agents, Levofloxacin, Metronidazole, Rifampicin, Spectrophotometric techniques, Sulfamethoxazole.



1. Introduction

Streptomycin was discovered in 1943 by Selman A. Waksman and Albert Schatz. Waksman introduced the term "antibiotic," which refers to a substance created by an organism to eradicate or stop the growth of other species (1). Pathogenic bacteria are those that cause bacterial infections and sickness. When they enter the body, start reproducing, displace beneficial bacteria, or develop into typically sterile tissues, they cause illnesses and ailments. Antibacterial medications, considered the most promising chemotherapeutic agents, have been discovered by researchers to treat infectious diseases (2). Although antibacterials are life-saving medications, improper use can result in antibiotic resistance, a significant public health risk. The rise of antibiotic-resistant bacterial infections is one of the major factors contributing to increased morbidity and mortality, especially in the elderly and individuals with medical conditions (3,4).

Antibacterials, a subclass of antibiotics, have previously been categorized in several ways; however, to make it more straightforward, antibacterial agents can be divided into five categories (5). Based on their mode of action, antibacterials can usually be divided into bacteriostatic (like Sulfamethoxazole) and bactericidal (i.e., Levofloxacin, Metronidazole, and Rifampicin). While bactericidal antibacterials aim to kill germs by attacking their cell wall or membranes, bacteriostatic antibacterials work to slow or prevent bacterial growth (6).

A subclass of antibiotics known as antibacterials can be produced synthetically, chemically altered from naturally existing substances, or spontaneously from fungal sources (7). Classification by activity spectrum is another way of classifying antibiotics or antimicrobials based on target specification. In this category, antibiotics are either narrow-spectrum (Metronidazole) or broad-spectrum (Levofloxacin, Rifampicin, Sulfamethoxazole). Generally, a narrow-spectrum antibiotic is favored over a broad-spectrum antibiotic, which is ideal. This is because narrow-spectrum antibiotics are less likely to result in superinfections than broad-spectrum antibiotics. After all, they do not entirely eradicate the body's usual microbes. Bacteria become less immune as a result (8). A variety of skeletal antibiotics display various curative behaviors. As a result, it is crucial to categorize antibiotics according to their molecular structure. This classification is also vital because comparable structural units share similar toxicity, potency, and other related properties. Antibiotics are typically split structurally into β -lactams (group A) and aminoglycosides (group B). However, β -lactam/ β -lactamase, β -lactams inhibitor mixtures, amine glycosides, quinolones, macrolides, and fluoroquinolones are more specific antibiotic categories (5). Function refers to a substance's mode of operation or mode of activity. One of the most crucial aspects of antimicrobial agents is this. Cell membrane function, cell wall synthesis, nucleic acid synthesis, protein synthesis, etc., are the primary processes or activities in bacterial growth. Antibiotics can be used to treat any one of these mechanisms. Antibiotics can be divided into four categories based on how they interfere with or disrupt these processes: inhibitors of cell wall synthesis, protein synthesis inhibitors (Metronidazole, etc.), membrane function inhibitors, and nucleic acid synthesis inhibitors (Levofloxacin, Rifampicin, Sulfamethoxazole, etc.) (9). This study aims to investigate the simultaneous analysis of specific antibacterial spectrophotometrically.

2. Materials and Methods

2.1. Levofloxacin

Levofloxacin (**Figure 1a**), chemically is 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-hydrate (2:1), (S)-; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, hemihydrate (10). It is a third-generation broad-spectrum fluoroquinolone antibiotic used to treat bacterial infections such as acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, acute bacterial prostatitis, and acute pyelonephritis. Levofloxacin was patented in 1987 and subsequently in the United States in 1996 for treating hospital-acquired pneumonia, community-acquired pneumonia, urinary tract infections, and skin or skin structure infections. Also, it is used to prevent and treat plaque caused by *Yersinia pasties*. Levofloxacin was FDA-approved to control the progression of inhaled anthrax (11,12).

2.2. Metronidazole

As an antiprotozoal, antiamebic, and antibacterial medication, Metronidazole with chemical formula (2-(2-Methyl-5-nitro-1H-imidazol-1-yl) ethanol) (13) **Figure 1b**, is a bactericidal synthetic derivative of azomycin. Due to its effectiveness against anaerobic bacteria and protozoa, it has a wide range of applications. In the human liver, Metronidazole is converted into more polar metabolites. Metronidazole is the best option for colitis brought on by *Clostridium difficile* (14–16).

2.3. Rifampicin

Rifampicin (**Figure 1c**) is a semi-synthetic antibiotic derived from rifamycin SV and is chemically ((2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[[[(4-methylpiperazin-1-yl) imino] methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca {1,11,13} trieneimino) naphtho[2,1-b] furan-21-yl acetate)) (13) active *in vitro* against microbacteria and gram-positive micro-organisms. Since its development, it has been used in veterinary and human medicine to treat tuberculosis and other mycobacterial infections (17,18).

2.4. Sulfamethoxazole

Sulfamethoxazole is a sulfonamide antibiotic (**Figure 1d**) with the IUPAC name (4-amino-N-(5-methylisoxazol-3-yl)-benzenesulfonamide) (13). Sulfamethoxazole inhibits bacterial dihydro-folate synthesis due to its structural similarity to para-aminobenzoic acid, an endogenous substrate that interferes with folate synthesis in susceptible bacteria (19). The emergence of resistant strains has limited its use, and it is now mainly used as a mixture with trimethoprim (20).




Figure 1. Structures formula of (a) Levofloxacin, (b) Sulfamethoxazole, (c) Metronidazole and (d) Rifampicin.

3. Results and Discussion

Several methods have been introduced to measure Levofloxacin, Sulfamethoxazole, Metronidazole, and Rifampicin separately or simultaneously. High-performance liquid chromatography, spectrophotometry, capillary electrophoresis, titration, spectrofluorometry, and voltammetry are a few examples. Simultaneous spectrophotometry is the most widely used due to its simplicity, sensitivity, and cost-effectiveness (21–23).

The primary application of UV spectrophotometry techniques is multicomponent analysis, which minimizes the laborious process of isolating interferences, shortens analysis time and expenses, and enables the measurement of more analytes (24). The foundation of multicomponent UV spectrophotometry is the documentation of standard absorption spectra and its mathematical analysis. The benefits of spectrophotometry are as follows: It is broadly applicable to both organic and inorganic systems while avoiding traditional separation methods, such as extraction, occupant enrichment, and potentially essential purification steps; spectral data acquisition is easy to acquire; detection limits typically of 10^{-4} - 10^{-5} M; reasonable to high selectivity and good accuracy (25).

Diverse spectrophotometry, Vierodt's method, derivative spectrophotometry, dual wavelength method, absorbance ratio spectral method, differential ratio spectral method, absorption coefficient method, continuous ratio differential spectral method, Q-absorption ratio method, isosbestic points method, and other techniques are all examples of multicomponent spectrophotometry. In addition, chemometric methods have been used for multicomponent analysis, including multivariate regression models, principal component analysis, partial least squares, parallel factor analysis, and artificial neural networks (26).

Table 1 illustrates a brief discussion of each method, including the combined drug(s), method(s), analytical results, and application remark.

Table 1. Spectrophotometric methods for simultaneous determination of Levofloxacin, Sulfamethoxazole, Metronidazole and Rifampicin.

Drug		Method(s)	Analytical Results	Application remark	Year	Ref
Target	Combined(s)					
Levofloxacin	Azithromycin	Area under curve method using DDQ and p-CA	$\lambda = (390-650) \text{ nm}$ and $(400-700) \text{ nm}$, Linearity range: $14.0-140.0 \text{ }\mu\text{g/mL}$ and $30-300.0\mu\text{g/mL}$, R^2 0.999 for both, Recovery 99.71-102.64% and 99.38-101.76%, LOD $1.40 \text{ }\mu\text{g/mL}$ and $3.00 \text{ }\mu\text{g/mL}$	Pure mixture, Pharmaceutical binary dosage forms	2019	(27)
	Azithromycin	Direct measurement of Abs in perchloric acid methanolic solution	$\lambda = 224\text{nm}$, Linearity range: $2.5-20.0 \text{ }\mu\text{g/mL}$, R^2 0.9991, Recovery 100.95%, LOD $0.80 \text{ }\mu\text{g/mL}$	Bulk powder, Laboratory-prepared tablets	2020	(28)
		First derivative peak-to-peak amplitudes	$\lambda = 280-253\text{nm}$, Linearity range: $5.0-40.0 \text{ }\mu\text{g/mL}$, R^2 0.9992, Recovery 100.53%, LOD $1.50 \text{ }\mu\text{g/mL}$			
	Atenolol, Paracetamol, and Hydrochlorothiazide	Extended derivative ratio	$\lambda = 282.8\text{nm}$, Linearity range: $1.0-15.0 \text{ }\mu\text{g/mL}$, R^2 0.9996, Recovery 100.15% LOD $0.25 \text{ }\mu\text{g/mL}$	Dosage forms, Human urine	2020	(29)
		Multivariate curve resolution - alternating least squares	$\lambda = (220.0-290.0) \text{ nm}$, Linearity range: $1.0-7.0 \text{ }\mu\text{g/mL}$, R^2 0.9999, Recovery 99.56%			
	Ambroxol	Absorbance ratio method	$\lambda = (244.6, 218.6)\text{nm}$, Linearity range: $3.0-7.0 \text{ }\mu\text{g/mL}$, R^2 0.9999, Recovery 99.0-100.0%, LOD $0.18 \text{ }\mu\text{g/mL}$	Tablets	2021	(30)
	Doxycycline	Absorbance ratio method, Simultaneous equation method	$\lambda = 287\text{nm}$, Linearity range: $2-20 \text{ }\mu\text{g/mL}$, R^2 0.9998, Recovery 99.66%, LOD $0.63 \text{ }\mu\text{g/mL}$	Synthetic mixture, Combined pharmaceutical dosage forms	2022	(31)
Metronidazole	Ornidazole	Area under curve method using DDQ and p-CA	$\lambda = (390-690)\text{nm}$ and $(400-700) \text{ nm}$, Linearity range: $10.0-200.0 \text{ }\mu\text{g/mL}$ and $30-600.0 \text{ }\mu\text{g/mL}$, R^2 0.998 and 0.999, Recovery 98.81-101.55% and 98.8-100.86%, LOD $3.3 \text{ }\mu\text{g/mL}$ and $9.9\mu\text{g/mL}$	Pure mixture, Pharmaceutical binary dosage forms	2022	(32)
	Spiramycin	Direct UV-spectrophotometry	$\lambda_{\text{max}} = 311 \text{ nm}$, Linearity range: $5-25 \text{ }\mu\text{g/mL}$, R^2 0.9997, Recovery 100.16%, LOD $0.3938\mu\text{g/mL}$	Pure form, Tablets	2010	(33)

Target	Drug Combined(s)	Method(s)	Analytical Results	Application remark	Year	Ref
		Ratio derivative spectrophotometry (¹ DD)	$\lambda_{\text{max}} = 311 \text{ nm}$, Linearity range: 5–25 $\mu\text{g/mL}$, R^2 0.9997, Recovery 100.16%, LOD 0.3938 $\mu\text{g/mL}$			
		Mean centring of the ratio spectra (MCR)	$\lambda = (200\text{--}400) \text{ nm}$, Linearity range: 5–25 $\mu\text{g/mL}$, R^2 1.0000, Recovery 101.1%, LOD 0.4967 $\mu\text{g/mL}$			
	Ciprofloxacin hydrochloride	Second derivative ratio spectrophotometry technique (² DD)	$\lambda = 301 \text{ nm}$, Linearity range: 4–16 $\mu\text{g/mL}$, R^2 0.9992, Recovery 100.21%, LOD 0.4900 $\mu\text{g/mL}$	Pure form, Tablets	2012	(34)
	Moxifloxacin	Partial least squares regression (PLS), Principal component regression (PCR)	$\lambda = 200\text{--}500 \text{ nm}$, Standard error of prediction (SEP): 0.036 (PLS), 0.043 (PCR) Prediction residual error sum-of squares (PRESS): 0.052 (PLS), 0.064 (PCR), Recovery: 99.4% (PLS), 99.43% (PCR)	Pharmaceutical tablets	2017	(35)
	Metronidazole benzoate	1 st and 2 nd derivative spectrophotometry	$\lambda = 200\text{--}350 \text{ nm}$, Linearity range: 1–25 $\mu\text{g/mL}$, R^2 0.9999, Recovery 99.75%–101.25%	Pharmaceutical preparations	2017	(36)
Rifampicin	Amoxicillin Trihydrate, Pantoprazole	Artificial Neural Networks	$\lambda = 200\text{--}400 \text{ nm}$, 3 layers feed-forward neural networks with the lower backward-spread set of rules, RMSE: 0.34	Tablets	2022	(37)
	Piperine	Q-Absorbance method	$\lambda = 387 \text{ nm}$, 337 nm, Linearity range: 5–40 $\mu\text{g/mL}$, R^2 0.999, Recovery 98.36–99.53%, LOD 1.51 $\mu\text{g/mL}$	Combined capsule	2012	(38)
	Isoniazid	Partial least squares regression (PLSR)	$\lambda = 449 \text{ nm}$, Linearity range: 8–57 $\mu\text{g/mL}$, Recovery 92–119%, RMSEP _{3LVs} 1.64 $\mu\text{g/mL}$	Urine, Pharmaceutical formulations	2013	(39)
	Isoniazid	Simultaneous equation	$\lambda = 338 \text{ nm}$, Linearity range: 5–50 $\mu\text{g/mL}$, R^2 0.992, Recovery 98.12–98.32%, LOD 3.50 $\mu\text{g/mL}$	Co-formulated tablets	2017	(40)
		First-derivative spectrophotometry	$\lambda = 263 \text{ nm}$, Linearity range: 5–50 $\mu\text{g/mL}$, R^2 0.996, Recovery 98.80–99.15%, LOD 2.30 $\mu\text{g/mL}$			

Target	Drug Combined(s)	Method(s)	Analytical Results	Application remark	Year	Ref
Sulfamethoxazole	Isoniazid, Pyrazinamide	First order derivative spectrophotometry	$\lambda = 322$ nm, Linearity range: 1.5-7.5 $\mu\text{g/mL}$, R^2 0.9927, Recovery 100.80%, LOD 0.03 $\mu\text{g/mL}$	Bulk form, Pharmaceutical dosage form	2020	(41)
	Isoniazid	Vierordt's method	$\lambda = 335$ nm, Linearity range: 6-36 $\mu\text{g/mL}$	Simulated Lungs Alveolar Macrophages Fluid	2022	(42)
	Trimethoprim	First derivative method	$\lambda = 288$ nm, Linearity range: 4-20 $\mu\text{g/mL}$, R^2 0.9999, Recovery 108.64%	Tablets, Syrups	1997	(43)
		Classical least squares (CLS) method	$\lambda = 200$ -350 nm, Linearity range: 4-20 $\mu\text{g/mL}$, Recovery 100.00%			
	Sulfacetamide	1 st derivative: Peak to baseline, Peak to peak, and Peak area	$\lambda = 219.75$ nm, (219.0, 253.0) nm, and (270.2-322.5)nm, Linearity range: 1–8 $\mu\text{g/mL}$, Recovery 98.9-101.4%	Synthetic Sample and Urine	2014	(44)
		2 nd derivative: Peak to baseline, Peak to peak, and Peak area	$\lambda = 275.0$ nm, (232.0, 275.0) nm, and (215.2-227.4)nm, Linearity range: 1–8 $\mu\text{g/mL}$, Recovery 98.1-102.3%			
		PLS1, PLS2	$\lambda = 190$ -350 nm, Linearity range: 1–8 $\mu\text{g/mL}$, Recovery 100.72%, 101.16%			
	Trimethoprim	Partial Least Square (PLS) regression	$\lambda = 200$ -400 nm, Linearity range: 1–16 $\mu\text{g/mL}$, R^2 0.99 RMSEC 0.167%, Recovery 100.72%, 101.16%	Combined Tablets	2015	(45)
	Trimethoprim	Mean Centering of Ratio Spectra (MCR)	$\lambda = 200$ -400 nm, Linearity range: 3.5–9.5 $\mu\text{g/mL}$, Recovery 103.31 $\pm$ 0.34%	Tablets	2018	(46)
	Trimethoprim	Aea under peak of SIA	$\lambda = 540$ nm and 264 nm, Linearity range: 0.1-10 $\mu\text{g/mL}$ and 0.03-5 $\mu\text{g/mL}$, R^2 0.9797 and 0.9928, LOD 0.01 and 0.03 $\mu\text{g/mL}$	Tablets	2020	(47)

4. Conclusion

Due to numerous benefits such patient compliance, timely dose administration, and fewer doses, multi-drug therapies and formulations are becoming increasingly important. Analytical chemists must pursue new directions and develop new, accurate, precise, cost-effective, time-effective, and simple methodologies to estimate pharmaceuticals in a multi-component system. Due to their inherent advantages, simultaneous analysis procedures are used more frequently for

drug estimation in multi-component pharmaceutical formulations. These advantages include avoiding time-consuming extraction and separation, being economical by using fewer expensive reagents, and being equally accurate and precise. According to the International Conference on Harmonization recommendations, techniques must be validated using the same parameters.

Acknowledgment

This work was partially supported by the Department of Chemistry/ College of Education for Pure Science (Ibn Al- Haitham)/ University of Baghdad.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Funding

No financial support was found.

Ethical Clearance

The study has been approved by the Committee of the University of Baghdad/ College of Education for Pure Science (Ibn Al-Haitham).

References

1. Kresge N, Simoni RD, Hill RL. Selman waksman: The father of antibiotics. J Biol Chem. 2004; 279(48):e7. [https://doi.org/10.1016/S0021-9258\(20\)67861-9](https://doi.org/10.1016/S0021-9258(20)67861-9).
2. Li D, Zhou B, Lv B. Antibacterial therapeutic agents composed of functional biological molecules. J Chem. 2020; 2020(6578579):1-13. <https://doi.org/10.1155/2020/6578579>
3. Mikhael EM, Hasan MK, Abdulridha SZ. Assessment of antibiotic knowledge among final year pharmacy students at Baghdad University. TOPHJ. 2019; 12(1):379-383. <https://doi.org/10.2174/1874944501912010379>
4. Miry SM, Al-Hayann HS. Antibacterial and anti-biofilm activities of iraqi propolis extracts against some antibiotic-resistant pathogenic bacteria. Iraqi J Biotechnol. 2022; 21(2):511-521.
5. Etebu E, Arikekpar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. Int J Appl Microbiol Biotechnol Res. 2016; 4(2016):90-101.
6. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010; 1:134. <https://doi.org/10.3389/fmicb.2010.00134>.
7. Oloke JK. Activity pattern of natural and synthetic antibacterial agents among hospital isolates. Microbios. 2000; 102(403):175-181.
8. Carbon C, Isturiz R. Narrow versus broad spectrum antibacterials: Factors in the selection of pneumococcal resistance to beta-lactams. Drugs. 2002; 62(9):1289-1294. <https://doi.org/10.2165/00003495-200262090-00001>.
9. Newton BA. Mechanisms of antibiotic action. Annu Rev Microbiol. 1965; 19(1):209-240. <https://doi.org/10.1146/annurev.mi.19.100165.001233>.
10. U.S. Pharmacopeia National Formulary (USP44-NF39), 2021.
11. Bush LM, Chaparro-Rojas F, Okeh V, Etienne J. Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy. Infect Drug Resist. 2011; 4:177-189. <https://doi.org/10.2147/IDR.S15610>.

12. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. *Drugs*. 2008; 68(4):535-565. <https://doi.org/10.2165/00003495-200868040-00011>.
13. British Pharmacopoeia. British Pharmacopoeia. 2022; Vol. 2, p. 302, 820, 1042.
14. Anjana GV. Synthesis and antimicrobial evaluation of deuterated analogues of metronidazole. *Iraqi J Pharm Sci*. 2022; 31(2):297-303. <https://doi.org/10.31351/vol31iss2pp297-303>.
15. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey K W, Gould CV, Kelly C, Loo V, Sammons JS, Sandora TJ, Wilcox MH. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. 2018; 66(7):e1-e48. <https://doi.org/10.1093/cid/cix1085>.
16. Dingsdag SA, Neil Hunter N. Metronidazole: An update on metabolism, structure–cytotoxicity and resistance mechanisms. *J Antimicrob Chemother*. 2018; 73(2):265-279. <https://doi.org/10.1093/jac/dkx351>.
17. Tawgozy F, Qarasnji BK. Molecular analysis of Rifampicin Resistance conferring mutations in mycobacterium tuberculosis. *Baghdad Sci J*. 2020; 17(2):444-451. <https://doi.org/10.21123/bsj.2020.17.2.0444>.
18. Al-Rubaye DS, Henihan G, Al-Abasly AKA, Seagar AL, Al-Attraqchi AAF, Schulze H, Hashim DS, Kamil JK, Laurenson IF, Bachmann TT. Genotypic assessment of drug-resistant tuberculosis in Baghdad and other Iraqi provinces using low-cost and low-density DNA microarrays. *J Med Microbiol*. 2016; 65(2):114-122. <https://doi.org/10.1099/jmm.0.000203>.
19. Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of *Plasmodium falciparum* to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. *Am J Trop Med Hyg*. 2003; 68(5): 586-589. <https://doi.org/10.4269/ajtmh.2003.68.586>.
20. Khalaf HS, Al-Haidari AM, Dikran SB, Mohammed AK. Spectrophotometric determination of sulfamethoxazole in pure and pharmaceutical preparations based on condensation reaction method. *JUBPAS*. 2017; 25(2):515-524.
21. Abraham S, Abdul kader S, Ibrahim S. Different analytical methods for the determination of metronidazole–A Review. *Int J Res Eng Innov*. 2020; 4(2):86-90. <https://doi.org/10.36037/IJREI.2020.4202>.
22. Kotadiya RM, Patel FN. Analytical methods practiced to quantitation of Rifampicin: A captious survey. *Curr Pharm Anal*. 2021; 17(8):983-999. <https://doi.org/10.2174/1573412916999200704144231>.
23. Biancolillo A, Marini F. Chemometric methods for spectroscopy-based pharmaceutical analysis. *Front Chem*. 2018; 6:576. <https://doi.org/10.3389/fchem.2018.00576>.
24. Gupta D, Bhardwaj S, Sethi S, Pramanik S, Kumar Das D, Kumar R, Pratap Singh P, Kumar Vashistha V. Simultaneous spectrophotometric determination of drug components from their dosage formulations. *Spectrochim Acta A Mol Biomol Spectrosc*. 2022; 270:120819. <https://doi.org/10.1016/j.saa.2021.120819>.
25. Skoog DA, Holler FJ, Crouch SR. Principles of Instrumental Analysis; 7th ed., Cengage Learning, U.S, 2018.
26. Sowjanya G, Chandaka PK. Chemometrics approach to drug analysis–An overview. *A J Pharm Tech Res*. 2019; 9(1):1-13. <https://doi.org/10.46624/ajptr.2019.v9.i1.001>.
27. Vittal SS, Veeraiah T, Reddy ChVR. Simultaneous spectrophotometric determination of levofloxacin and azithromycin using Π -acceptors as analytical reagents. *IOSR J Pharm*. 2019; 9(1):50-61. <https://doi.org/10.37285/ijpsn.2020.13.5.5>.

28. El-Yazbi AF, Khamis EF, Youssef RM, El-Sayed MA, Aboukhalil FM. Green analytical methods for simultaneous determination of compounds having relatively disparate absorbance; application to antibiotic formulation of azithromycin and levofloxacin. *Heliyon*. 2020; 6(9):e04819.
<https://doi.org/10.1016/j.heliyon.2020.e04819>.
29. Mostafa A. Spectrophotometric and multivariate calibration techniques for simultaneous determination of different drugs in pharmaceutical formulations and human urine: Evaluation of greenness profile. *J Anal Methods Chem*. 2020; 2020(1):8873003.
<https://doi.org/10.1155/2020/8873003>.
30. Bodhankar V, Thoke ST, Kouthekar VR, Deshmukh SM, Jadhao UT. Simultaneous estimation of ambroxol hydrochloride and levofloxacin hemihydrate using absorbance ratio method. *Eur J Pharm Med Res*. 2021; 8(3):640-645.
31. Gholve YN, Chaple DR, Kasliwal RH. Development and validation of novel analytical simultaneous estimation based UV spectrophotometric method for Doxycycline and Levofloxacin determination. *BRIAC*. 2022; 12(4):5458-5478. <https://doi.org/10.33263/BRIAC124.54585478>.
32. Ravi M, Veeraiah T, Venkata RRCh. Simultaneous spectrophotometric estimation of Levofloxacin and Ornidazole using DDQ and p-CA as analytical reagents. *J Pharm Sci & Res*. 2022; 14(9):901-907.
33. Khattab FI, Ramadan NK, Hegazy MA, Ghoniem NS. Simultaneous determination of metronidazole and spiramycin in bulk powder and in tablets using different spectrophotometric techniques. *Drug Test Anal*. 2010; 2(1):37-44. <https://doi.org/10.1002/dta.83>.
34. Alphonse M. Development and validation of a UV spectrophotometric method for the simultaneous determination of ciprofloxacin hydrochloride and metronidazole in binary mixture. *J Chem Pharm Res*. 2012; 4(11):4710-4715.
35. Ertokuş GP, Çelik UM. Chemometric analysis of Moxifloxacin and Metronidazole in binary drug combinations with spectrophotometric method. *EASJ*. 2017; 3(2):30-37.
36. Alsamarrai HAJ, Alsamarrai KF. Spectrophotometric determination of Metronidazole and Metronidazole benzoate via first and Second Derivative order spectroscopy. *Baghdad Sci J*. 2017; 14(2):320-327. <https://doi.org/10.21123/bsj.2017.14.2.0320>.
37. Hendawy H, Amin AS, Moalla SM, Aish MM. Artificial neural networks for the simultaneous spectrophotometric determination of Amoxicillin Trihydrate, Metronidazole and Pantoprazole in pharmaceutical formulations. *Egypt J Chem*. 2023; 66(6):119-127.
<https://doi.org/10.21608/ejchem.2022.151776.6582>.
38. Khamar JC, Patel SA. Q-Absorbance ratio spectrophotometric method for the simultaneous estimation of Rifampicin and Piperine in their combined capsule dosage. *J Appl Pharm Sci*. 2012; 2(4):137-141. <https://doi.org/10.7324/JAPS.2012.2416>.
39. Stets S, Tavares TM, Peralta-Zamora PG, Pessoa CA, Nagata N. simultaneous determination of Rifampicin and isoniazid in urine and pharmaceutical formulations by multivariate visible spectrophotometry. *J Braz Chem Soc*. 2013; 24(7):1198-1205.
<http://dx.doi.org/10.5935/0103-5053.20130154>.
40. Tilinca M, Hancu G, Mircia E, Iriminescu D, Rusu A, Vlad RA, Barabás E. Simultaneous determination of isoniazid and rifampicin by UV spectrophotometry. *Farmacia*. 2017; 65(2):219-224.
41. Khawas S, Parui S, Dey S, Mondal SK, Sarkar S. Simultaneous spectrophotometric estimation of Rifampicin, Isoniazid and Pyrazinamide in their pharmaceutical dosage form. *Asian J Research Chem*. 2020; 13(2):117-122. <https://doi.org/10.5958/0974-4150.2020.00024.3>.

42. Bhoyar V, Belgamwar VS, Trivedi S. Simultaneous determination and validation of anti-tubercular drugs in simulated lungs alveolar macrophages fluid by ultraviolet-visible spectrophotometric method. *J Appl Spectrosc.* 2022; 89(5):892-897. <https://doi.org/10.1007/s10812-022-01444-z>.
43. Mohamed EM. Simultaneous spectrophotometric determination of Sulfamethoxazole and Trimethoprim in drugs. *Anal Lett.* 1997; 30(13):2341-2352. <https://doi.org/10.1080/00032719708001746>.
44. Samar A. Development and validation of new methods for simultaneous spectrophotometric determination of Sulfamethoxazole and Sulfacetamide drugs in their pure forms, Synthetic Samples and Urine, Doctoral dissertation, University of Baghdad, Baghdad, 2014.
45. Rohman A, Silawati D, Sudjadi, Riyanto S. Simultaneous determination of Sulfamethoxazole and Trimethoprim using UV spectroscopy in combination with multivariate calibration. *J Med Sci.* 2015; 15(4):178-184. <https://doi.org/10.3923/jms.2015.178.184>.
46. Muchlisyam, Pardede Tr, Satiawan R. Determination of simultaneous Sulfamethoxazole and Trimethoprim by ultraviolet spectrophotometry with mean centering of ratio spectra. *Asian J Pharm Clin Res.* 2018; 11(1):61. <https://doi.org/10.22159/ajpcr.2018.v11s1.26569>.
47. Nesmerak K, Kroihherova A, Baptistova A, Hranicek J. Spectrometric determination of trimethoprim and sulfamethoxazole in tablets by automated sequential injection technique. *Monatsh Chem.* 2020; 151(8):1311-1316. <https://doi.org/10.1007/s00706-020-02631-4>.